Foundational guide
Epithalon Protocol: Experimental Design, Not Clinical
A protocol exists so that someone else can repeat the work. For a compound whose findings come mostly from one group, that is the property that matters most.
Ask for the epithalon protocol and what arrives is a quantity, a frequency and a number of days. Ask what a protocol is for, and the answer is different: a protocol exists so that a laboratory with no connection to the original work can carry out the same procedure and find out whether the same thing happens.
That test, repeatability by a stranger, is the one this compound most needs and least satisfies. Its findings come principally from Khavinson and colleagues in St Petersburg, and independent replication outside that group is limited. A document that cannot be handed to an unaffiliated laboratory is not doing the job the word describes.
Supplier publishing lot-level data
Epithalon, Ascension Peptides
This batch carries a Kovera Labs certificate reporting purity, identity, endotoxin, sterility and heavy metals. The code below halves the listed price on the vial.
The certificate for batch 15-05260628 assays this vial at 9.64 mg against a 10 mg label, inside the stated 10 percent tolerance, which puts the real figure at $2.59/mg on that batch. It carries purity, identity, endotoxin, sterility and heavy metals. Buying 3, 5 or 10 takes 3%, 5% or 10% off list.
- Kovera Labs certificate, batch 15-05260628
- Carriage free above $250
- Dispatched same day before 2pm CST
Supplied for laboratory research use and not for human consumption. Affiliate links: a commission may be earned at no cost to the reader, and it does not affect the assessment above. Prices verified September 8, 2026.
Repeatability is the property, not detail for its own sake
A research protocol is written before the work begins and specifies enough that the procedure can be executed by someone who was not in the room. That requirement drives everything else in the document. Material provenance has to be stated, because a different supplier is a different substance. Handling and storage have to be stated, because degradation is invisible. Outcome and instrument have to be stated, because two laboratories measuring differently will disagree for reasons unrelated to the compound. The analysis has to be stated in advance, because an analysis chosen after seeing the data can manufacture a result from noise.
Every one of these exists to protect against a specific way of being wrong. Strip them out and what remains is a schedule, which protects against nothing.
The reproduction test, item by item
| Specification item | Why an unaffiliated laboratory needs it | What its absence permits |
|---|---|---|
| Material source, batch and purity testing | A different synthesis is a different substance | Disagreement attributed to biology when it belongs to chemistry |
| Storage, reconstitution and handling | Peptides degrade invisibly under the wrong conditions | Two laboratories exposing subjects to materially different substances |
| Species, strain and housing conditions | Rodent outcomes shift with colony, diet and environment | Results that depend on the facility rather than the compound |
| Exposure level, route and timing | These are the experimental variables | An unrepeatable procedure |
| Outcome definition and instrument | Different assays answer different questions | Apparent replication that measured something else |
| Blinded outcome assessment | Expectation influences measurement, including in animal work | Systematic drift toward the expected result |
| Control condition | Change over time happens without intervention | Attribution of ordinary variation to the compound |
| Analysis plan fixed in advance | Post hoc analysis can produce findings from noise | Selective reporting that no reader can detect |
| Public registration before starting | Makes the plan checkable against the report | Unnoticed changes between plan and publication |
Circulating advice for this compound supplies exactly one row, the fourth, and frequently states it without a route attached. The other eight rows are not abbreviated in those documents. They are absent, and their absence is never marked, so a reader has no way to notice what was left out.
What makes a replication independent
The word independent does real work in that last answer, and it is worth defining, because partial independence is common and is often reported as the full article.
A laboratory that received its material from the original group is not fully independent, since any property of that material travels with it. A study using the same assay from the same supplier, run by someone trained in the original laboratory, shares more method than it appears to. A report published without enough procedural detail for a third party to repeat it again is not a replication either, whatever its result, because it cannot be checked in turn.
Genuine independence means separate material provenance, separate personnel, separate facilities, and no stake in the outcome. It also means the replicating group is free to publish a negative result, which is a condition about incentives rather than about method, and one that quietly determines what a literature looks like.
Applied to this compound, the point is not that anyone has failed such a test. It is that the test has largely not been run. That leaves the findings in a defined category rather than a rejected one, and the category should be stated whenever the findings are.
Why the earlier preparation does not supply a protocol either
Some writing about this compound reaches back to the pineal peptide preparation it descended from, treating procedures used with that preparation as a source of guidance.
That inheritance fails at the first step. The parent was an extract from animal tissue, a mixture whose composition varied by source and by batch, and whose active constituents were not fully characterised. A procedure written for an extract specifies handling of a substance that is not this one. Results obtained with a mixture do not belong to any single component of it without separate work to demonstrate that they do.
There is a further reason the older material is a poor guide. Reproducibility standards, blinding practice, prospective registration and reporting requirements have all changed substantially over the decades in which this research programme developed. Reading older work by the standards now applied is not a criticism of researchers who followed the conventions of their time. It is a statement about how much weight a modern reader can place on it without independent confirmation, which is exactly what remains missing.
The epithalon protocol that would be worth writing
The productive version of this question is not what to follow but what to write.
A useful design would begin with the least glamorous claim rather than the most striking one. Not lifespan, which requires long observation and is notoriously sensitive to housing and diet in rodents, but a short horizon biochemical measurement that an independent laboratory could complete in a defined period. It would specify material from a supplier unconnected to the original programme, with identity and content confirmed before use. It would include a control group and blinded outcome assessment, since expectation influences measurement in animal experiments as well as human ones. It would register the outcome and the analysis before starting, and it would commit to publication regardless of direction.
A study of that shape is unremarkable in design and would be far more informative than another repetition of the original claims, because it would supply the one thing the existing literature lacks: an observation made by people who did not already believe the answer.
The gap between those two documents is where most confusion about an epithalon protocol lives, and naming it removes the confusion without pretending to resolve the underlying uncertainty.
What this leaves for the reader who wanted a schedule
There is no protocol to give, and the reason is worth being exact about. It is not that the compound has been examined and dismissed, and it is not that nothing has ever been studied. Real experiments exist, and they sit in a category, findings awaiting independent confirmation, that is distinct from established results.
A schedule extracted from that literature and posted online inherits the uncertainty and drops the label. That is the transaction taking place whenever a research quantity gets reprinted as advice.
Frequently asked questions
- Is there a registered protocol for this compound anywhere?
- No. No registered interventional trial exists, so there is no registered protocol to read, and no registry identifier can honestly be cited for this compound. Searches that appear to return trials are matching text in unrelated records.
- If the original research described a procedure, why can I not follow it?
- Because a procedure described in an experimental report is a description of what one group did in one facility, with their material, their animals and their measurements. Following it reproduces the numbers, not the conditions, and the conditions are what a result depends on.
- Would a very carefully documented personal log qualify?
- No. Documentation quality is not the missing element. A log has one participant, no control condition, no blinding and an outcome usually chosen after something was noticed. Improving the notes does not add any of those.
- Does the number of people following the same schedule matter?
- Not in the way it appears to. Many people running the same undesigned procedure produce many undesigned observations, plus a reporting filter, since those who noticed nothing generally do not write it up.
- What would an independent replication actually look like?
- An unaffiliated laboratory obtaining material from its own supplier, running the described procedure with a control group and blinded assessment, and publishing the outcome whichever way it came out. That last clause is part of the definition.
Limitations of the evidence
No protocol, schedule, quantity or route appears on this page, and none is recommended. No registered interventional trial of this compound exists, so there is no registered protocol to read and no trial registry identifier is cited. The experimental work this compound descends from is concentrated in the research programme of Khavinson and colleagues in St Petersburg, and independent replication outside that group is limited, which leaves those findings in a category awaiting confirmation rather than a rejected one. Procedures written for the parent pineal extract describe a mixture rather than this peptide and do not transfer to it. The study design described in the closing sections is an account of what would be informative, not a report of work that has been carried out. Epithalon holds no marketing authorisation in any market and nothing here describes or recommends human use.